Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
A new study published in The BMJ has found that adults with type 2 diabetes who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), may face a higher risk of developing non-scarring hair loss (alopecia) compared with patients taking other commonly prescribed diabetes medicines
A detailed dosage chart for weight loss could look like: Initial Phase During the initial phase, a lower dose of 2.5 mg once a week is recommended
Previous allergic reaction to any GLP-1 or GIP agonist medication History of reactions to injectable medications in general Multiple documented drug allergies Skin conditions affecting injection sites like eczema or psoriasis Immune system disorders or immunosuppressive therapy History of severe allergic reactions to any substance First-Time Injectable Users People new to self-administered injections sometimes experience more pronounced local reactions initially
Research-only products are not approved for human use
Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes
US$ 25.10
US$ 21.29
US$ 22.55
